Regulation of inflammation in cancer by eicosanoids.

[1]  Y. Lou,et al.  Effects of high-fat diets rich in either omega-3 or omega-6 fatty acids on UVB-induced skin carcinogenesis in SKH-1 mice. , 2011, Carcinogenesis.

[2]  K. Weylandt,et al.  Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-α. , 2011, Carcinogenesis.

[3]  D. Steinhilber,et al.  Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. , 2011, The Journal of clinical investigation.

[4]  C. Serhan.  The resolution of inflammation: the devil in the flask and in the details , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Garret A. FitzGerald,et al.  Prostaglandins and Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[6]  M. Hull,et al.  Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer , 2011, Gut.

[7]  E. Chan,et al.  Ultra-pressure liquid chromatography/tandem mass spectrometry targeted profiling of arachidonic acid and eicosanoids in human colorectal cancer. , 2011, Rapid communications in mass spectrometry : RCM.

[8]  Xiuli Liu,et al.  Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival , 2011, Cancer Chemotherapy and Pharmacology.

[9]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[10]  C. Serhan,et al.  Novel anti-inflammatory--pro-resolving mediators and their receptors. , 2011, Current topics in medicinal chemistry.

[11]  A. Brash,et al.  The Structure of Human 5-Lipoxygenase , 2011, Science.

[12]  J. Falck,et al.  Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer , 2011, Cancer Chemotherapy and Pharmacology.

[13]  Dongmei Guo,et al.  Circulating LTD4 in patients with hepatocellular carcinoma , 2011, Tumor Biology.

[14]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[15]  Jin-Ho Kim,et al.  Western‐style diets induce macrophage infiltration and contribute to colitis‐associated carcinogenesis , 2010, Journal of gastroenterology and hepatology.

[16]  Sui Huang,et al.  Cytochrome P450-derived eicosanoids: the neglected pathway in cancer , 2010, Cancer and Metastasis Reviews.

[17]  C. Serhan.  Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? , 2010, The American journal of pathology.

[18]  Jun Yu,et al.  Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. , 2010, Cancer letters.

[19]  J. Folkman,et al.  Inhibition of tumor angiogenesis by oral etoposide. , 2010, Experimental and therapeutic medicine.

[20]  D. Ye,et al.  Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis , 2010, Molecular Cancer Therapeutics.

[21]  J. Liao,et al.  Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. , 2010, American journal of translational research.

[22]  J. Wallace,et al.  A pro-resolution mediator, prostaglandin D2, is specifically up-regulated in individuals in long-term remission from ulcerative colitis , 2010, Proceedings of the National Academy of Sciences.

[23]  P. Kogner,et al.  Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? , 2010, Experimental cell research.

[24]  B. Chandran,et al.  Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen. , 2010, Cancer research.

[25]  P. Allavena,et al.  Inflammation-mediated promotion of invasion and metastasis , 2010, Cancer and Metastasis Reviews.

[26]  B. Levy.  Resolvins and protectins: natural pharmacophores for resolution biology. , 2010, Prostaglandins, leukotrienes, and essential fatty acids.

[27]  A. Mantovani,et al.  Cancer and Inflammation: Implications for Pharmacology and Therapeutics , 2010, Clinical pharmacology and therapeutics.

[28]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[29]  C. Serhan,et al.  Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  C. Wood,et al.  Tumorigenesis and Neoplastic Progression Loss of 15-Hydroxyprostaglandin Dehydrogenase Expression Contributes to Bladder Cancer Progression , 2010 .

[31]  R. DuBois,et al.  The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.

[32]  T. Sawada,et al.  Reduction of 15‐hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma , 2010, Cancer science.

[33]  T. Lawrence,et al.  The resolution of inflammation and cancer. , 2010, Cytokine & growth factor reviews.

[34]  F. Olivieri,et al.  Lipoxygenase inhibitors for cancer prevention: promises and risks. , 2010, Current pharmaceutical design.

[35]  J. Haeggström,et al.  Fundamentals of Inflammation: Lipid Mediators in Acute Inflammation and Resolution: Eicosanoids, PAF, Resolvins, and Protectins , 2010 .

[36]  Bruce D. Hammock,et al.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases , 2009, Nature Reviews Drug Discovery.

[37]  R. Roman,et al.  Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. , 2009, Anticancer research.

[38]  H. Claésson,et al.  On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma. , 2009, Prostaglandins & other lipid mediators.

[39]  D. Ye,et al.  Lipoxin A4 inhibited hepatocyte growth factor‐induced invasion of human hepatoma cells , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[40]  S. Nonogaki,et al.  Leukotriene B4 Creates a Favorable Microenvironment for Murine Melanoma Growth , 2009, Molecular Cancer Research.

[41]  Zhi Wang,et al.  Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2 , 2009, The Journal of Laryngology & Otology.

[42]  O. Monni,et al.  15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Gastric Cancer , 2009, Clinical Cancer Research.

[43]  Honglin Li,et al.  [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. , 2009, Cancer research.

[44]  R. Totah,et al.  Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology , 2009, Expert opinion on drug metabolism & toxicology.

[45]  C. Godson,et al.  Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. , 2009, American journal of physiology. Cell physiology.

[46]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[47]  Randall Harris,et al.  Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung , 2009, Inflammopharmacology.

[48]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[49]  P. Reddanna,et al.  Eicosanoids in inflammation and cancer: the role of COX-2 , 2009, Expert review of clinical immunology.

[50]  T. Hattori,et al.  A selective cyclooxygenase‐2 inhibitor prevents inflammation‐related squamous cell carcinogenesis of the forestomach via duodenogastric reflux in rats , 2009, Cancer.

[51]  達脇 大.  Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma , 2009 .

[52]  J. J. Moreno.  New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. , 2009, Biochemical pharmacology.

[53]  Wan-Wan Lin,et al.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis , 2009, Nature.

[54]  Sui Huang,et al.  PPARs: A Double-Edged Sword in Cancer Therapy? , 2009, PPAR research.

[55]  H. Friess,et al.  The Role of PPARγ Receptors and Leukotriene B4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer , 2009, PPAR research.

[56]  M. Toner,et al.  Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution1 , 2008, The Journal of Immunology.

[57]  C. Fan,et al.  PGE2 and LTB4 tissue levels in benign and cancerous prostates. , 2008, Prostaglandins & other lipid mediators.

[58]  N. Lehman,et al.  Expression of CYP4A1 in U251 Human Glioma Cell Induces Hyperproliferative Phenotype in Vitro and Rapidly Growing Tumors in Vivo , 2008, Journal of Pharmacology and Experimental Therapeutics.

[59]  K. Izumi,et al.  Soluble EP2 neutralizes prostaglandin E2–induced cell signaling and inhibits osteolytic tumor growth , 2008, Molecular Cancer Therapeutics.

[60]  R. Yantiss,et al.  NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase Regulates Levels of Bioactive Lipids in Non–Small Cell Lung Cancer , 2008, Cancer Prevention Research.

[61]  M. Ono.  Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy , 2008, Cancer science.

[62]  J. Lupton,et al.  Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. , 2008, Cancer research.

[63]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[64]  P. Clark,et al.  Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. , 2008, Cancer research.

[65]  G. Aust,et al.  Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma. , 2008, Anticancer research.

[66]  R. Schneiter,et al.  Lipid signalling in disease , 2008, Nature Reviews Molecular Cell Biology.

[67]  S. Laufer,et al.  Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. , 2008, Carcinogenesis.

[68]  Sui Huang,et al.  PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.

[69]  K. Honn,et al.  Eicosanoids in tumor progression and metastasis. , 2008, Sub-cellular biochemistry.

[70]  A. Mantovani,et al.  Cancer: Inflaming metastasis , 2008, Nature.

[71]  D. Noonan,et al.  Inflammation, inflammatory cells and angiogenesis: decisions and indecisions , 2008, Cancer and Metastasis Reviews.

[72]  Sriram Krishnamoorthy,et al.  Lipoxygenase metabolism: roles in tumor progression and survival , 2007, Cancer and Metastasis Reviews.

[73]  F. Marincola,et al.  Comparative Analysis of Peritoneum and Tumor Eicosanoids and Pathways in Advanced Ovarian Cancer , 2007, Clinical Cancer Research.

[74]  D. Nie,et al.  Cyclooxygenases, prostanoids, and tumor progression , 2007, Cancer and Metastasis Reviews.

[75]  Louise R Howe,et al.  Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer , 2007, Breast Cancer Research.

[76]  K. Kiguchi,et al.  Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice , 2007, Molecular Cancer Therapeutics.

[77]  James P Edwards,et al.  Anti-Inflammatory Activity of a Potent, Selective Leukotriene A4 Hydrolase Inhibitor in Comparison with the 5-Lipoxygenase Inhibitor Zileuton , 2007, Journal of Pharmacology and Experimental Therapeutics.

[78]  P. Sinha,et al.  Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. , 2007, Cancer research.

[79]  Toby Lawrence,et al.  Inflammation and cancer: a failure of resolution? , 2007, Trends in pharmacological sciences.

[80]  M. Hambek,et al.  Inverse correlation between serum PGE2 and T classification in head and neck cancer , 2007, Head & neck.

[81]  P. Krieg,et al.  Inducible expression of 15-lipoxygenase-2 and 8-lipoxygenase inhibits cell growth via common signaling pathways Published, JLR Papers in Press, December 11, 2006. , 2007, Journal of Lipid Research.

[82]  A. A. Spector,et al.  Action of epoxyeicosatrienoic acids on cellular function. , 2007, American journal of physiology. Cell physiology.

[83]  Sui Huang,et al.  PPARα Deficiency in Inflammatory Cells Suppresses Tumor Growth , 2007, PloS one.

[84]  Henry J. Lin,et al.  Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. , 2007, Cancer research.

[85]  Raymond N DuBois,et al.  NSAIDs and cancer prevention: targets downstream of COX-2. , 2007, Annual review of medicine.

[86]  I. Fleming.  Epoxyeicosatrienoic acids, cell signaling and angiogenesis. , 2007, Prostaglandins & other lipid mediators.

[87]  K. Rainsford,et al.  Anti-inflammatory drugs in the 21st century. , 2007, Sub-cellular biochemistry.

[88]  Sui Huang,et al.  PPAR\(\alpha\) Deficiency in Inflammatory Cells Suppresses Tumor Growth , 2007 .

[89]  Á. Lanas,et al.  Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. , 2006, Prostaglandins & other lipid mediators.

[90]  J. Baron,et al.  A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. , 2006, Gastroenterology.

[91]  B. Aggarwal,et al.  Inflammation and cancer: how hot is the link? , 2006, Biochemical pharmacology.

[92]  D. Carbone,et al.  Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. , 2006, Cancer research.

[93]  C. Dinarello,et al.  The paradox of pro-inflammatory cytokines in cancer , 2006, Cancer and Metastasis Reviews.

[94]  B. Hammock,et al.  Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[95]  D. Grant,et al.  Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms , 2006, Journal of Molecular Histology.

[96]  M. Yaqoob,et al.  COX-2 in inflammation and resolution. , 2006, Molecular interventions.

[97]  B. Karlan,et al.  15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. , 2006, Cancer research.

[98]  J. Falck,et al.  9L Gliosarcoma Cell Proliferation and Tumor Growth in Rats Are Suppressed by N-Hydroxy-N′-(4-butyl-2-methylphenol) Formamidine (HET0016), a Selective Inhibitor of CYP4A , 2006, Journal of Pharmacology and Experimental Therapeutics.

[99]  W. See,et al.  Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. , 2006, Cancer letters.

[100]  J. Leips,et al.  Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression1 , 2006, The Journal of Immunology.

[101]  C. Clish,et al.  The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. , 2005, Biochemical and biophysical research communications.

[102]  S. Narumiya,et al.  Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. , 2005, Carcinogenesis.

[103]  J. Falck,et al.  Human U251 Glioma Cell Proliferation Is Suppressed by HET0016 [N-Hydroxy-N′-(4-butyl-2-methylphenyl)formamidine], a Selective Inhibitor of CYP4A , 2005, Journal of Pharmacology and Experimental Therapeutics.

[104]  J. Wallace,et al.  Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. , 2005, The American journal of pathology.

[105]  Amanda J. Thomas,et al.  A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.

[106]  V. Ooi,et al.  Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[107]  A. Pozzi,et al.  Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids* , 2005, Journal of Biological Chemistry.

[108]  B. Hammock,et al.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[109]  A. Mantovani,et al.  Cancer: Inflammation by remote control , 2005, Nature.

[110]  M. Flattery,et al.  COX-2 inhibitors and cardiovascular risk. , 2005, Progress in cardiovascular nursing.

[111]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[112]  T. Adrian,et al.  LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. , 2005, Neoplasia.

[113]  B. Wong,et al.  Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. , 2005, Carcinogenesis.

[114]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[115]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[116]  N. Narayanan,et al.  A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. , 2005, International journal of oncology.

[117]  Eunjung Kim,et al.  An antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis , 2005, Oncogene.

[118]  H. Tai,et al.  15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Colorectal Cancer* , 2005, Journal of Biological Chemistry.

[119]  N. Lecture.  Adventures and Excursions in Bioassay: The Stepping Stones to Prostacylin , 2005 .

[120]  J. Falck,et al.  Human U 251 Glioma Cell Proliferation Is Suppressed by HET 0016 [ N-Hydroxy-N-( 4-butyl-2-methylphenyl ) formamidine ] , a Selective Inhibitor of CYP 4 A , 2005 .

[121]  Charles N. Serhan,et al.  Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers , 2004, Lipids.

[122]  W. Wu,et al.  Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. , 2004, Toxicology.

[123]  D. Beer,et al.  Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis , 2004, Clinical Cancer Research.

[124]  Hans Clevers,et al.  At the Crossroads of Inflammation and Cancer , 2004, Cell.

[125]  S. Dey,et al.  Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ , 2004 .

[126]  L. Dwyer-Nield,et al.  Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. , 2004, Carcinogenesis.

[127]  S. Narumiya,et al.  Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development , 2004, Gut.

[128]  Michael T. Lotze,et al.  Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.

[129]  T. Adrian,et al.  Effect of LY293111 in combination with gemcitabine in colonic cancer. , 2004, Cancer letters.

[130]  J. Lewin,et al.  Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.

[131]  D. Gilroy,et al.  A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[132]  W. Walker,et al.  Prostaglandin E2 is a potent regulator of interleukin‐12‐ and interleukin‐18‐induced natural killer cell interferon‐γ synthesis , 2004, Immunology.

[133]  R. DuBois,et al.  Cyclooxygenase-2: a potential target in breast cancer. , 2004, Seminars in oncology.

[134]  H. Guski,et al.  Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters , 2001, Clinical & Experimental Metastasis.

[135]  J. Tímár,et al.  12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis , 1994, Cancer and Metastasis Reviews.

[136]  J. Vane,et al.  Adventures and Excursions in Bioassay: The Stepping Stones to Prostacylin , 1983, Bioscience reports.

[137]  S. Dey,et al.  Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. , 2004, Cancer cell.

[138]  G. Anderson,et al.  Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. , 2003, Cancer research.

[139]  Mei-Due Yang,et al.  Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma. , 2003, Oncology reports.

[140]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[141]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[142]  K. Asadullah,et al.  An Aspirin-Triggered Lipoxin A4 Stable Analog Displays a Unique Topical Anti-Inflammatory Profile , 2002, The Journal of Immunology.

[143]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[144]  Susan M. Kilroy,et al.  PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. , 2002, The Journal of clinical investigation.

[145]  V. Steele,et al.  Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. , 2002, Cancer research.

[146]  Kazuhiro Usui,et al.  Proinflammatory Cytokine IL-1β Promotes Tumor Growth of Lewis Lung Carcinoma by Induction of Angiogenic Factors: In Vivo Analysis of Tumor-Stromal Interaction1 , 2002, The Journal of Immunology.

[147]  J. Wallace.  Nutritional and Botanical Modulation of the Inflammatory Cascade—Eicosanoids, Cyclooxygenases, and Lipoxygenases— As an Adjunct in Cancer Therapy , 2002, Integrative cancer therapies.

[148]  R. Roman,et al.  P-450 metabolites of arachidonic acid in the control of cardiovascular function. , 2002, Physiological reviews.

[149]  S. Narumiya,et al.  Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. , 2002, Cancer research.

[150]  T. Sugimura,et al.  Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. , 2001, Carcinogenesis.

[151]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[152]  D. Zeldin.  Epoxygenase Pathways of Arachidonic Acid Metabolism* , 2001, The Journal of Biological Chemistry.

[153]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[154]  B D Hammock,et al.  Soluble Epoxide Hydrolase Regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic Acids , 2000, Circulation research.

[155]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[156]  C. Clish,et al.  Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.

[157]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[158]  C. McArdle,et al.  Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer. , 2000, Nutrition.

[159]  Hugh R. Brady,et al.  Cutting Edge: Lipoxins Rapidly Stimulate Nonphlogistic Phagocytosis of Apoptotic Neutrophils by Monocyte-Derived Macrophages1 , 2000, The Journal of Immunology.

[160]  Y. Mahida,et al.  The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. , 2000, Inflammatory bowel diseases.

[161]  S. Narumiya,et al.  Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. , 1999, Cancer research.

[162]  R. Busse,et al.  Cytochrome P450 2C is an EDHF synthase in coronary arteries , 1999, Nature.

[163]  C. Myers,et al.  Lipoxygenase Inhibition in Prostate Cancer , 1999, European Urology.

[164]  B. Calvo,et al.  Expression of 15-lipoxygenase-1 in human colorectal cancer. , 1999, Cancer research.

[165]  K. Honn,et al.  12(S)-HETE in cancer metastasis. , 1999, Advances in experimental medicine and biology.

[166]  K. Fearon,et al.  Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. , 1999, Clinical science.

[167]  C. Myers,et al.  Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[168]  D. Grignon,et al.  Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. , 1998, Cancer research.

[169]  P. Lipsky,et al.  Cyclooxygenase in biology and disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[170]  A. Castonguay,et al.  Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. , 1998, Carcinogenesis.

[171]  C. Myers,et al.  Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. , 1997, Biochemical and biophysical research communications.

[172]  M. H. Lee,et al.  Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549)–Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation , 1996, Molecular medicine.

[173]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[174]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[175]  B. Rigas,et al.  Altered eicosanoid levels in human colon cancer. , 1993, The Journal of laboratory and clinical medicine.

[176]  D. Zeldin,et al.  Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. , 1993, The Journal of biological chemistry.

[177]  M. D. del Río.  [Ulcerative colitis and cancer]. , 1992, Acta gastroenterologica Latinoamericana.

[178]  G. Siest,et al.  Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells. , 1991, General pharmacology.

[179]  H. Adami,et al.  Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.

[180]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[181]  M. Boyd,et al.  Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. , 1988, Cancer research.

[182]  M. Hamberg,et al.  Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[183]  B. Samuelsson.  FROM STUDIES OF BIOCHEMICAL MECHANISMS TO NEW BIOLOGICAL MEDIATORS: PROSTAGLANDIN ENDOPEROXIDES, THROMBOXANES, AND LEUKOTRIENES , 1984 .

[184]  B. Samuelsson.  From studies of biochemical mechanism to novel biological mediators: Prostaglandin endoperoxides, thromboxanes, and leukotriences , 1983 .

[185]  P. Alexander.  Prostaglandins and cancer , 1982, Nature.

[186]  Nobelstiftelsen.  Les Prix Nobel : Nobel Prizes, presentations, biographies and lectures , 1982 .

[187]  T. Grosser,et al.  PROSTANOIDS IN HEALTH AND DISEASE , 1979 .

[188]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[189]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[190]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.